Repurposing cysteamine as a rapdily deployable intervention for COVID-19

Nylexa是一种重新调整用途的疗法，已经在针对CF患者胸部感染的晚期开发中，可以迅速应用于新冠肺炎的治疗。Nylexa是独一无二的，可能会改变游戏规则，因为它有多个靶点；NSARS-CoV-2病毒，对感染的免疫反应，以及继发于SARS-CoV-2的难治性细菌感染的并发症，目前导致多达20%的新冠肺炎死亡，超过50%的暴发(在湖北省，中国)。Nylexa是一种抗微生物免疫调节剂，有可能改变这种疾病的发展轨迹。以挽救生命，帮助那些感染了永久性肺损伤较少的人更好地康复。Nylexa可以在英国住院的新冠肺炎患者身上进行快速安全的测试(作为静脉输注药物)，然后在世界范围内进行测试。Nylexa不仅是伟大的科学，也是治疗新冠肺炎的真正可行的解决方案：成本效益高、容易获得和可扩展，这样它就可以在成功、快速的临床测试和批准后部署到所需的全球规模。作为一家开发一流抗感染和呼吸道疾病疗法的领先生物技术公司，NovaBiotics完全有能力实现这一结果。该公司在开发从发明到后期临床开发和此后通过与具有制造和销售基础设施的制药实体的伙伴关系开发新药候选药物方面有着良好的记录。Nylexa不仅可以改变新冠肺炎大流行的结果，而且可以改变NovaBiotics的结果。Nylexa可能成为NovaBiotics的第一个获批药物，并可能使业务转向盈利，使公司得以发展，并对研发进行再投资，以推进该公司治疗细菌和真菌疾病的其他可能挽救生命的抗菌药物，这些药物可能会比Nylexa对社会和经济产生更大的好处。

Nylexa is a repurposed therapy, already in advanced development for chest infections in CF patients, that can be rapidly deployed as a treatment for COVID-19\.Nylexa is unique and potentially game-changing, because it has multiple targets; the nSARS-CoV-2 virus, the immune response to the infection and also the complications of intractable bacterial infections secondary to SARS-CoV-2 that result in as many as 20% of COVID-19 deaths currently and more than 50% early in the outbreak (in Hubei Province, China).Nylexa is an antimicrobial-immunomodulator with the potential to alter the trajectory of this disease. To save lives and aid better recovery of those infected with less permanent lung damage. It can be rapidly and safely tested (as an intravenously infused drug) in hospitalised COVID-19 patients in the UK and thereafter, worldwide.Nylexa isn't just great science, it is a truly viable solution to COVID-19: Cost effective, readily available and scalable, such that it can be deployed on the global scale required post successful, expedited clinical testing and approvals. NovaBiotics is perfectly positioned to deliver this outcome as a leading biotechnology company developing first-in-class anti-infective and respiratory disease therapies. The business has a track record of developing novel drug candidates from invention to late stage clinical development and commercialisation thereafter through partnerships with pharmaceutical entities with manufacturing and sales-distribution infrastructure.Nylexa could not only be transformational on outcomes of the COVID-19 pandemic, but for NovaBiotics. Nylexa could potentially become NovaBiotics' first approved drug and could pivot the business to profitability, allowing company growth and re-investment in research and development to advance the company's other, potentially life-saving antimicrobial medicines for bacterial and fungal disease, which could have even greater benefit to society and the economy than Nylexa.